MSACL 2019 US Abstract

A Proteomic Predictor of Lipoprotein Function and Coronary Artery Disease: From Conception to Launch

Timothy S. Collier (1), Zhicheng Jin (1), Darlene L.Y. Dai (2), Virginia Chen (2), Zsuzsanna Hollander (2), Raymond T. Ng (2), Bruce M. McManus (2), Robert Balshaw (2), Sophia Apostolidou (3), Marc S. Penn (1), Cory Bystrom (1)
(1) Quest Diagnostics -Cleveland HeartLab Cardiometabolic Center of Excellence, Cleveland, OH (2) PROOF Centre of Excellence, Vancouver, BC, Canada (3) 3. Gynaecological Cancer Research Centre, Department of Women

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Timothy Collier (Presenter) Quest Diagnostics - Cleveland HeartLab

Presenter Bio: Dr. Timothy Collier is an Associate Scientific Director for Quest Diagnostics - Cleveland HeartLab Cardiometabolic Center of Excellence, where he oversees the technical performance of laboratory operations. Previously as a Sr. R&D Scientist, his responsibilities included the identification and development of assays for cardiovascular biomarkers. Prior to joining Cleveland HeartLab, he was a Post-Doctoral Research Scholar in Molecular Oncology and Hematology at Washington University School of Medicine in St. Louis, MO, focusing on the identification of drug-resistance mechanisms and structural studies of cancer-driving mutations using quantitative mass spectrometry.

Relevant Financial Disclosures (within past 24 months) Committee/Board/Advisory Board MSACL Scientific Committee Stock/Bonds Quest Diagnostics Salary Quest Diagnostics Discussing Products? YES, presenter will present educational content related to products/services of one or more ineligible company(ies) listed above. Conflict mitigation IN PROCESS.

High-density lipoproteins are complex, and cardiovascular health depends on their functional properties, not only their concentration. Cholesterol efflux capacity is one function that is associated with cardiovascular disease. However, the traditional cell-based assay lacks precision and scalability. Here we describe the conception, development, validation, and evaluation of a multi-marker proteomic method and accompanying algorithms for estimation of cholesterol efflux capacity (pCE) and prediction of coronary artery disease (pCAD). Measurement of both demonstrated consistent association with cardiovascular disease in multiple case-control studies. The precise and scalable nature of the method enables larger future studies to explore clinical utility.